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Fighting the Malignancy of
Recurring Heart Failure Events*
Frieder Braunschweig, MD, PHD
Stockholm, Sweden
Contrary to the trivializing label “frequent flyer,” which
conjures analogies to rewards from airline bonus programs,
recurrent hospital stays for heart failure (HF) constitute a
truly malignant condition that has a detrimental impact on
patient prognosis and health care consumption. Patients
who are hospitalized for HF have a highly increased risk
for repeat hospital stay and death. Approximately one-
half of such patients will be rehospitalized at least once
within the following 6 months, and up to 35% will die
within 1 year (1).
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This grim outlook was recently substantiated by data
from the CHARM (Candesartan in Heart Failure: Assess-
ment of Reduction in Mortality and Morbidity) trial, which
showed a 3-fold increased risk of mortality in patients
who were discharged after a hospital stay for HF (2).
Moreover, if patients experienced a third admission for HF,
their hazard ratio for first-month mortality increased nearly
15-fold. Similar findings of an incremental mortality risk
with repeated admissions for HF were described in a large
community population (3). These observations suggest that
recurrent HF events are an independent marker of adverse
outcomes and should be subject of specific evaluation in HF
trials.
Despite this, few studies have examined recurrent HF
events in greater detail. This might be partly due to
statistical difficulties in determining the appropriate value
for repeated endpoints, particularly if hospital stay and
mortality are evaluated as a composite outcome measure.
Nevertheless, although time-to-first-event values seem to be
clearer, they can be misleading, because single early admis-
sions generate a worse statistical outcome than multiple
admissions occurring later on (4). Consequently, composite
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relationships to disclose.endpoints, such as “days alive and out of hospital,” have
been increasingly used as a primary or secondary study
objective.
Although the understanding of causal factors for recur-
rent HF remains incomplete, there is good reason to assume
that this phenomenon reflects conditions that are not
sufficiently described by first-event analyses. Gheorghiade et
al. (5) hypothesized that repetitive hemodynamic deteriora-
tion and neurohormonal activation triggered by volume
exacerbations cause myocardial damage and thus accelerate
disease progression and contribute to further impairment of
ventricular function. Similarly, frequent in-hospital treat-
ment of decompensated HF with intravenous diuretics and
inotropic drugs has been associated with myocardial injury,
worsening renal function, and adverse clinical outcomes (6).
n addition, recurrent HF events might identify patients
ho are chronically noncompliant with regard to treatment
rescriptions and lifestyle advice.
In this issue of the Journal, Goldenberg et al. (7) present
ata from the MADIT-CRT (Multicenter Automatic De-
brillator Implantation Trial with Cardiac Resynchroniza-
ion Therapy) trial on the effect of cardiac resynchronization
herapy (CRT) on recurring HF events in patients with
ild HF, left ventricular systolic dysfunction, and signs of
lectromechanical dyssynchrony. This article contains sev-
ral important messages. First, consistent with studies in
ew York Heart Association functional class III/IV pa-
ients (8,9), treatment with an implantable cardiac defibril-
ator (ICD) with CRT capabilities (CRT-D) markedly
educed the risk for a first HF event by 46%, compared with
CD alone. This improvement was comparable to results
rom 2 previous trials in similar populations (10,11).
Second, and most important, the report describes novel
ndings in which the former conclusions on morbidity
eduction by CRT remained valid when patients were
valuated further into the course of HF after they had
xperienced a first HF event. This finding is a major
xtension of our knowledge about the long-term effects of
RT and strengthens recent guideline updates concerning
he use of CRT in New York Heart Association functional
lass II patients (12). Notably, it also suggests that signifi-
ant treatment benefits can still be achieved at a later stage
f CRT and in patients who might prematurely be classified
s nonresponders after an early HF exacerbation but in
hom progressive reverse remodeling nevertheless translates
nto delayed clinical improvement.
Third, the authors highlight the malignancy of recurrent
F events by demonstrating a 7-fold and nearly 19-fold
ncrease in the risk of subsequent all-cause mortality after a
rst and second post-enrollment episode, respectively, em-
hasizing recurrent HF events as an important risk marker
nd necessitating a thorough reassessment of medical treat-
ent, device programming, and disease management strat-
gies in affected individuals. At this, monitoring of HF-
elevant parameters with diagnostic features of the CRT-D
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treatment guidance. Repeated HF episodes might also
trigger decisions concerning last-resort interventions with
mechanical assist devices and heart transplantation on one
end and termination of any advanced treatment on the
other.
Finally, consistent with results from the main trial pub-
lication (13), the present study confirms the important role
of typical left bundle branch block (LBBB) pattern as a
powerful predictor of favorable CRT response in the setting
of recurrent HF. Of note, the previously reported favorable
outcomes in female study participants seem to be largely
attributable to the high prevalence of LBBB in this sub-
group.
However, the remarkable reduction in HF-related hos-
pital stays and outpatient visits by CRT should be put in
perspective with all-cause health care use, which unfortu-
nately was not addressed in the present article. In contrast to
insertion of an ICD without CRT capabilities, the addition
of a left ventricular lead is associated with excess perioper-
ative complications, such as dissection and perforation of
the coronary sinus, phrenic nerve capture, and lead dislodg-
ment (14). These and other device-related problems com-
monly cause prolonged initial hospital stays, repeat hospital
stays, and extra visits and can offset the gains in HF-specific
endpoints.
It is also well-known that HF-related admissions only
account for a minority of overall hospital stays in HF
patients, who typically have a complex comorbidity profile
and frequently present for noncardiovascular diagnoses. For
example, after 24 months of follow-up in the European
REVERSE (REsynchronization reVErses Remodeling in
Systolic Left vEntricular Dysfunction) cohort, HF hospital
stay rates fell significantly in patients who were assigned to
CRT ON versus OFF (7.8% vs. 18.4%), whereas all-cause
hospital stay was similar in the 2 groups (40.5% vs. 41.2%).
Finally, although the ICD component was not evaluated
with a control in this study, ICD therapy is nevertheless
associated with increased health care use—for example, due
to more frequent HF episodes (15) and the delivery of
inappropriate and unnecessary shocks.
Yet, the MADIT-CRT investigators should be acknowl-
edged for putting the focus on recurrent HF events and
establishing the effectiveness of CRT in reducing this
important endpoint in select patients with mild HF. As-
pects of long-term treatment efficacy are particularly impor-
tant in the assessment of implantable devices, for which
evaluations of clinical response, complications, and costs are
too often restricted to a brief period after implantation. The
present article offers a view beyond the horizon of a first
HF event and demonstrates the value of CRT, even in
this scenario, a perspective that should be provided by mmore trials that evaluate interventions in patients with
chronic HF.
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